DIABETIC RETINOPATHY MARKET ANALYSIS

Regional Analysis

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the diabetic retinopathy market, holding 36.2% of the market share in 2024, driven by the high prevalence of diabetes, advanced healthcare infrastructure, and the presence of key market players. The region benefits from well-established healthcare systems and increased access to diagnostic and treatment options, supporting its leadership in the market.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region is projected to experience the fastest growth due to its large and growing diabetic population, increasing awareness about diabetic retinopathy, and rising healthcare expenditures in emerging economies like China and India. The region's expanding healthcare infrastructure and ongoing initiatives to improve access to eye care services are expected to significantly boost market growth in the coming years.

Diabetic Retinopathy Market Outlook for Key countries

Growing Diabetes Prevalence and Approvals Drive Market Expansion in the U.S.

The U.S. diabetic retinopathy market is driven by the increasing prevalence of diabetes, according to the National Library of Medicine in June 2023, with an estimated 4.1 million individuals aged 40 and older affected by diabetic retinopathy as of 2023. Moreover, In August 2023, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals' EYLEA (aflibercept) Injection for the treatment of retinopathy of prematurity (ROP) in preterm infants.

Rising Diabetes Cases and Government Initiatives Boost Diabetic Retinopathy Market in India

The India diabetic retinopathy market is expanding due to the rising prevalence of diabetes and government initiatives such as National Program for Control of Blindness and Visual Impairment to improve eye care services. In August 2021, Siemens Healthineers, a medical technology company, inaugurated a manufacturing facility in Gujarat, India with a production capacity of 25 million tests per annum, aimed at enhancing molecular testing infrastructure in the country.

Advancements in Molecular Diagnostics Fuel Market Growth in Germany

The Germany diabetic retinopathy market is influenced by advancements in molecular diagnostic techniques. In November 2024, Microbiologics, a biotechnology company, acquired SensID, a Germany-based manufacturer specializing in molecular diagnostics for oncology and precision medicine, strengthening its portfolio in oncology while maintaining leadership in infectious disease diagnostics.

Increasing Diabetes Rates and Adoption of Advanced Diagnostics Propel Market Growth in China

China diabetic retinopathy market growth is driven by the increasing prevalence of diabetes and the adoption of advanced diagnostic technologies. In June 2024, Bio-Rad Laboratories, a life science company, expanded its molecular quality control portfolio with the launch of Exact Diagnostics GBS Positive and Negative Run Controls, designed for Group B Streptococcus molecular assays, enhancing diagnostic accuracy.